Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Phase I Study of the Safety and Immunogenicity of a Novel H5N1 Influenza Vaccine in Healthy Adults Age 18-49 Years

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01560793

Enrollment

224

Registered

2012-03-22

Start date

2012-06-30

Completion date

2013-11-30

Last updated

2014-09-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Influenza

Keywords

Influenza, Vaccines, H5N1

Brief summary

This study will evaluate the safety and immunogenicity of VAX161B \[STF2.HA5 H5N1\], a recombinant, inactivated, subunit influenza vaccine given as a two dose regimen at a range of doses.

Detailed description

The purpose of this study is to test an investigational vaccine known as VAX161B. VAX161B is a vaccine for the influenza A virus subtype H5N1 avian influenza virus (bird flu). In this study, the subject will receive the VAX161B vaccine at one of five doses to see which does might be the best. VaxInnate want to find out how safe these vaccines are and how well they are tolerated by people who receive them. To measure how effective each type of vaccine is, VaxInnate will test the ability of the body to develop an immune response, which means how well the body recognizes and defends itself against the influenza virus.

Interventions

BIOLOGICALVAX161 [STF2.HA5 H5N1]

dose escalating, 2 intramuscular doses given 21 days apart

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 49 Years

Healthy volunteers

Yes

Inclusion criteria

* male or female aged 18 - 49 years inclusive * give written informed consent to participate * healthy, as determined by medical history, physical examination * comprehension of the study requirements * willing to provide multiple blood specimens collected by venipuncture.

Exclusion criteria

* Subjects who have a psychiatric illness, a chronic illness that would interfere with participation or interpretation of results * clinically significant abnormal liver function tests * positive serology for HBsAg or HCV antibodies * impaired immune responses * history of anaphylactic type reaction to injected vaccines * history of drug or chemical abuse in the year prior to screening * history of Guillain-Barré Syndrome * history of chronic obstructive pulmonary disease or history of other lung disease

Design outcomes

Primary

Measure	Time frame	Description
Safety	1 year	Assess safety, reactogenicity and tolerability. Symptoms will be collected from the memory aid and from the information collected at the clinic visits. All symptoms will be graded according to severity. Response to vaccine will be categorized as local (arm pain, redness, bruising, etc.) or systemic (headache, muscle aches, fatigue, etc.) symptoms. Laboratory tests such as CRP, WBC, LFTs and cytokines collected before and after vaccination will also be analyzed. We will compare the types and severity of symptoms and laboratory results based on vaccine dose.

Secondary

Measure	Time frame	Description
Immunogenicity	6 mos.	To assess serum immune response, sera collected at Days 0, 21, 42 and 180 will be analyzed for HAI, MN, serum IgG anti-HA and serum IgG anti-flagellin by Elisa. The geometric mean, seroconversion and seroprotection rates will be determined.

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026